RGBP (Regen BioPharma) Operating Cash Flow per Share : $-0.09 (TTM As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Regen BioPharma Operating Cash Flow per Share?

Regen BioPharma's operating cash flow per share for the three months ended in Sep. 2024 was $-0.01. Regen BioPharma's operating cash flow per share for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.09.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 33.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Regen BioPharma's Operating Cash Flow per Share or its related term are showing as below:

RGBP' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: 2.5 Med: 17.9 Max: 73.9
Current: 33.2

During the past 12 years, Regen BioPharma's highest 3-Year average Operating Cash Flow per Share Growth Rate was 73.90% per year. The lowest was 2.50% per year. And the median was 17.90% per year.

RGBP's 3-Year OCF Growth Rate is ranked better than
82.06% of 1193 companies
in the Biotechnology industry
Industry Median: 3.6 vs RGBP: 33.20

Regen BioPharma Operating Cash Flow per Share Historical Data

The historical data trend for Regen BioPharma's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regen BioPharma Operating Cash Flow per Share Chart

Regen BioPharma Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Operating Cash Flow per Share

Get a 7-Day Free Trial

0.01

-0.28

-0.10

-0.03

-0.08

Regen BioPharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Operating Cash Flow per Share	Get a 7-Day Free Trial															-	-0.02	-0.03	-0.02	-0.01

Competitive Comparison of Regen BioPharma's Operating Cash Flow per Share

For the Biotechnology subindustry, Regen BioPharma's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regen BioPharma's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's Price-to-Operating-Cash-Flow falls into.

Regen BioPharma Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Regen BioPharma's Operating Cash Flow per Share for the fiscal year that ended in Sep. 2024 is calculated as

Operating Cash Flow per Share (A: Sep. 2024 )	=	Cash Flow from Operations (A: Sep. 2024 )	/	Shares Outstanding (Diluted Average) (A: Sep. 2024 )
	=	-0.693	/	8.221
	=	-0.08

Regen BioPharma's Operating Cash Flow per Share for the quarter that ended in Sep. 2024 is calculated as

Operating Cash Flow per Share (Q: Sep. 2024 )	=	Cash Flow from Operations (Q: Sep. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Sep. 2024 )
	=	-0.149	/	10.516
	=	-0.01

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.09

Regen BioPharma Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Regen BioPharma's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Regen BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBP) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

RGBPP.PFD:USA

Address

4700 Spring Street, Suite 304, La Mesa, CA, USA, 91942

Website

https://www.regenbiopharmainc.com

Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.